Phaseline

Targets › MCL1

MCL1 (Induced myeloid leukemia cell differentiation protein Mcl-1): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2029.

Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. (UniProt, Q07820)

Open in Phaseline: the race on MCL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ascentage Pharma GroupAPG-3288
Dual BCL-2 and MCL-1 inhibitor
BCL2, MCL1, BCL-XLPhase 1Relapsed/Refractory Hematological MalignanciesDec 2029
Ascentage Pharma GroupAPG-1252
BCL-2 family protein inhibitor
BCL2, BCL2L1, BCL2L2, MCL1Phase 1EGFR Positive Non-small Cell Lung Cancer–

Conditions

Relapsed/Refractory Hematological Malignancies (1) EGFR Positive Non-small Cell Lung Cancer (1)

Modalities

small molecule (2)

Companies

Ascentage Pharma Group (2)

Related targets

BCL2 (2) BCL-XL (1) BCL2L1 (1) BCL2L2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.